| __timestamp | Corcept Therapeutics Incorporated | Supernus Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 882000 | 5758000 |
| Thursday, January 1, 2015 | 1361000 | 8423000 |
| Friday, January 1, 2016 | 2058000 | 11986000 |
| Sunday, January 1, 2017 | 3554000 | 15215000 |
| Monday, January 1, 2018 | 5215000 | 15356000 |
| Tuesday, January 1, 2019 | 5504000 | 16660000 |
| Wednesday, January 1, 2020 | 5582000 | 52459000 |
| Friday, January 1, 2021 | 5281000 | 75061000 |
| Saturday, January 1, 2022 | 5385000 | 87221000 |
| Sunday, January 1, 2023 | 6481000 | 83779000 |
Unleashing insights
In the competitive landscape of biopharmaceuticals, cost efficiency is a critical metric. This analysis delves into the cost of revenue trends for Corcept Therapeutics and Supernus Pharmaceuticals from 2014 to 2023. Over this period, Corcept Therapeutics demonstrated a steady increase in cost efficiency, with costs rising from approximately $882,000 in 2014 to $6.5 million in 2023. This represents a growth of over 600%, reflecting strategic scaling and operational optimization.
Conversely, Supernus Pharmaceuticals experienced a more volatile trajectory, with costs peaking at $87 million in 2022, a staggering 1,400% increase from 2014. This fluctuation suggests a dynamic approach to market expansion and product development. Understanding these trends provides valuable insights into the financial strategies of these industry players, highlighting the balance between growth and cost management.
Cost of Revenue Trends: Regeneron Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.
Biogen Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Comparing Cost of Revenue Efficiency: Viatris Inc. vs Corcept Therapeutics Incorporated
Intra-Cellular Therapies, Inc. vs Corcept Therapeutics Incorporated: Efficiency in Cost of Revenue Explored
Analyzing Cost of Revenue: Jazz Pharmaceuticals plc and Supernus Pharmaceuticals, Inc.
Cost of Revenue: Key Insights for Halozyme Therapeutics, Inc. and Corcept Therapeutics Incorporated
Cost Insights: Breaking Down Lantheus Holdings, Inc. and Supernus Pharmaceuticals, Inc.'s Expenses
Analyzing Cost of Revenue: Corcept Therapeutics Incorporated and Bausch Health Companies Inc.
Cost of Revenue Trends: ADMA Biologics, Inc. vs Supernus Pharmaceuticals, Inc.
Amneal Pharmaceuticals, Inc. vs Supernus Pharmaceuticals, Inc.: Efficiency in Cost of Revenue Explored
Cost of Revenue: Key Insights for Supernus Pharmaceuticals, Inc. and Xencor, Inc.
Cost Insights: Breaking Down Supernus Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.'s Expenses